Abstract. In order to clarify the molecular mechanism involved in thyroid carcinogenesis and to identify candidate molecular targets for diagnosis and treatment, we analyzed genome-wide gene expression profiles of 18 papillary thyroid carcinomas with a microarray representing 38,500 genes in combination with laser microbeam microdissection. We identified 243 transcripts that were commonly up-regulated and 138 transcripts that were down-regulated in thyroid carcinoma. Among these 243 transcripts identified, only 71 transcripts were reported as up-regulated genes in previous microarray studies, in which bulk cancer tissues and normal thyroid tissues were used for the analysis. We further selected genes that were overexpressed very commonly in thyroid carcinoma, though were not expressed in the normal human tissues examined. Among them, we focused on the regulator of G-protein signaling 4 (RGS4) and knocked-down its expression in thyroid cancer cells by small-interfering RNA. The effective down-regulation of its expression levels in thyroid cancer cells significantly attenuated viability of thyroid cancer cells, indicating the significant role of RGS4 in thyroid carcinogenesis. Our data should be helpful for a better understanding of the tumorigenesis of thyroid cancer and could contribute to the development of diagnostic tumor markers and molecular-targeting therapy for patients with thyroid cancer.
Introduction
Thyroid carcinoma represents 1% of all malignant diseases and accounts for nearly 90% of neuroendocrine malignancies. Papillary thyroid carcinoma (PTC) is the most common malignant thyroid tumor, representing 80-90% of thyroid malignancies. Papillary, follicular and anaplastic thyroid carcinomas are known to arise from follicular epithelial cells while medullary thyroid carcinomas arise from the parafollicular C cells of the thyroid. PTC is usually welldifferentiated; however, the clinical characteristics of PTC vary widely. For example, incidental microcarcinomas are often noninvasive or minimally invasive and grow very slowly. However, invasive PTC often causes metastasis and can be lethal. PTCs often recur many years after their surgical operation. The prognosis for PTC is frequently favorable, though ~20% of patients with PTC experience recurrence and some of them die of the disease (1, 2) . A postoperative follow-up for monitoring recurrence is critically important for a favorable outcome. Although PTC can be diagnosed by a cytological examination of fine-needle aspiration materials, this method is not applicable for the prediction of a postoperative clinical outcome. Serum thyroglobulin (TG) immunoassay has been used for monitoring the recurrence of differentiated thyroid carcinoma, though measurement of serum TG is sometimes hindered by the presence of circulating factors, particularly anti-TG antibodies and a residual normal thyroid gland tissue that produces TG (3) .
The genome-wide microarray analysis enabled us to obtain comprehensive gene expression profiles related to phenotypic and biological information in cancer cells (4) (5) (6) (7) (8) (9) (10) . We have identified multiple applicable targets for the development of novel anti-cancer drugs and/or diagnostic markers. For thyroid carcinoma, this approach is useful for identifying unknown molecules involved in the carcinogenic pathway (5, (11) (12) (13) (14) .
Through gene expression profile analysis of 18 papillary thyroid cancers coupled with the purification of the cancer cell population by laser microbeam microdissection (LMM) on a microarray consisting of ~38,500 transcripts, we identified a number of transcripts that were overexpressed in thyroid cancers. We report important information regarding the mechanisms of thyroid carcinogenesis as well as the discovery of potential targets for the development of diagnostic markers and signal-suppressing therapeutic strategies for thyroid cancer treatment.
Materials and methods
Tissue samples and microdissection. Eighteen thyroid cancer tissue samples (17 female and 1 male patients; median age, 46 years; range, 20-71 years; Table I ) were obtained with written informed consent along with adjacent normal thyroid tissue samples from patients undergoing surgery at the Clinic of Endocrine Surgery (Sofia, Bulgaria). These cancer tissues were histopathologically diagnosed as papillary thyroid carcinoma. Clinical information was obtained from medical records. Clinical stage was judged according to the UICC TNM classification. Each speciman was embedded in TissueTek OCT medium (Sakura, Tokyo, Japan) immediately after surgical resection and stored at -80˚C until use. These frozen tissues were cut into 8-μm sections using a cryostat (Sakura) and then stained with hematoxylin and eosin (H&E) for histological examination. Thyroid cancer cells and corresponding normal thyroid epithelial cells were selectively collected using the EZ cut system with a pulsed ultraviolet narrow beam-focus laser (SL Microtest GmbH, Jena, Germany) according to the manufacturer's protocols. RNA isolated from the microdissected normal thyroid follicular epithelial cells of 13 individuals was mixed and used as a 'universal control' for each of the 18 cancer samples.
Cell lines.
The human thyroid carcinoma cell line, FTC-133, was used in this study. FTC-133 was grown in a monolayer in appropriate media supplemented with 10% fetal calf serum (FCS) and 1% antibiotic/antimycotic solution (SigmaAldrich). FTC-133 was maintained at 37˚C in an atmosphere of humidified air with 5% CO 2 .
Affymetrix GeneChip hybridization. The Affymetrix human genome U133 Plus 2.0 GeneChip arrays were used for microarray hybridizations. This GeneChip comprises of >54,000 probe sets and analyzes the expression level of >47,000 transcripts. For microarray hybridization, we followed the protocol described in the Affymetrix GeneChip eukaryotic two cycles target preparation protocol (Affymetrix). For the first-round synthesis of double-stranded cDNA, 100 ng of total RNA were reverse transcribed using the two-cycle cDNA synthesis kit (Affymetrix, Santa Clara, CA) and T7-oligo-dT primer according to the manufacturer's instructions followed by IVT amplification with the MEGAscript T7 kit (Ambion, Inc., Austin, TX). After cleanup of the cRNA with a GeneChip sample cleanup module IVT column (Affymetrix), second-round double-stranded cDNA was amplified using the IVT labeling kit (Affymetrix). A 20 μg aliquot of the labeled product was fragmented by heat and ion-mediated hydrolysis at 94˚C for 35 min in H 2 O and 8 μl of 5x fragmentation buffer (Affymetrix). The fragmented cRNA was hybridized for 16 h at 45˚C in a hybridization oven 640 to a U133 Plus 2.0 oligonucleotide array (Affymetrix). The washing and staining of the arrays with phycoerythrin-conjugated streptavidin (Molecular Probes, Eugene, OR) was completed in a fluidics station 450 (Affymetrix). The arrays were then scanned using a confocal laser GeneChip scanner 3000 (Affymetrix).
Data analysis. Global normalization at a target value of 500 was applied to each of the 19 arrays (18 cancer arrays and one array of the universal control) under consideration using GeneChip operating software (Affymetrix). Normalized data from text files were imported to a Microsoft Excel spread sheet. Since data derived from low signal intensities are less reliable, we excluded transcripts with low intensities from further analysis when the signal intensities of both normal and cancer cells were lower than that of the cut-off. For the other genes, we calculated the signal intensities of cancer/ normal ratio using the raw data of each sample. We selected up-regulated or down-regulated genes based on their signal intensities of cancer/normal ratios (r): up-regulated (r>5.0) and down-regulated (r<0.2).
Calculation of contamination percentage. Calcitonin (CALCA), a hormone that is expressed exclusively in parafollicular C cells, was used to evaluate the proportion of C cells present in the population of microdissected normal follicular epithelial cells. Each intensity was normalized to the Table I. Clinical features of PTC clinical samples used for  microarray analysis.  -------------------------------------------------No  Age  Gender  Clinical Stage  -------------------------------------------------TH_T_1  37  Female  III  TH_T_3  69  Female  III  TH_T_4  54  Female  II  TH_T_6  22  Female  III  TH_T_7  60  Female  II  TH_T_8  58  Female  II  TH_T_9  34  Female  III  TH_T_10  71  Male  III  TH_T_11  64  Female  II  TH_T_13  49  Female  I  TH_T_14  28  Female  III  TH_T_15  47  Female  I  TH_T_16  26  Female  III  TH_T_20  44  Female  II  TH_T_21  36  Female  II  TH_T_26  45  Female  II  TH_T_28  20  Female  II  TH_T_31 59
intensity of the ß actin gene (ACTB) as follows: (Ratio A) the CALCA/ACTB intensity ratio in whole normal thyroid tissue (where some of the cells correspond to C cells); the signal intensity of poly (A) + RNA isolated from whole normal thyroid tissue was 0.18.
(Ratio B) the CALCA/ACTB intensity ratio in microdissected normal follicular epithelial cells = 0.0046 (a mixture of normal follicular epithelial cells from 13 individuals as a universal control). On the basis of these measurements, the proportion of contaminated C cells in microdissected normal follicular epithelial cells was calculated to be 2.6%.
Semi-quantitative RT-PCR.
RNAs from the purified populations of thyroid cancer cells and from normal follicular epithelial cells were extracted using an RNeasy micro kit (Qiagen, Valencia, CA) and were treated with DNase I according to the recommendation of the manufacturer. Extracted RNAs were subjected to two rounds of RNA amplification using T7-based in vitro transcription (Invitrogen) and amplified RNAs were reverse transcribed to singlestranded cDNAs using a random primer with Superscript II reverse transcriptase (Invitrogen). We prepared appropriate dilutions of each single-stranded cDNA for subsequent PCR amplification and monitored their reactions using GAPDH as a quantitative control since this showed the smallest fluctuations of cancer/normal ratio in our thyroid cancer microarray data. PCR amplification was performed using single-strand cDNAs as templates and gene-specific primers (Table II) . PCR reactions were optimized for the number of cycles to ensure product intensity within the logarithmic phase of amplification.
Northern blot analysis. Human multiple tissue Northern blots (MTN) (BD Biosciences, Palo Alto, CA) were hybridized for 16 h with 32 P-labeled PCR product of the regulator of Gprotein signaling 4 (RGS4) cDNA. The cDNA probe of RGS4 was prepared by RT-PCR using the primers 5'-GACAAAG TGGTTATTTGCCAGAG-3' and 5'-AGGTGAGAATTAG GCACACTGAG-3'. Prehybridization, hybridization and washing were performed according to manufacturer's recommendations. The blots were autoradiographed with intensifying screens at -80˚C for 14 days.
Effect of small interfering RNAs on the growth of thyroid cancer cells. In order to evaluate the biological significance of RGS4 in thyroid cancer cells, we used the psi-U6BX3.0 vector for the expression of short hairpin RNA against the target gene, as described previously (15) . The U6 promoter was cloned upstream of the gene-specific sequence (19-nucleotide sequence from the target transcript, separated from the reverse complement of the same sequence by a short spacer, (TTCAAGAGA), with five thymidines as a termination signal and a neo-cassette for selection by Geneticin (Sigma). Plasmids designed to express small interfering RNA (siRNA) were prepared by the cloning of double-stranded oligonucleotides into the psi-U6BX vector (Table III) .
Human thyroid cancer cells, FTC-133, which express RGS4 at a high level, were plated onto 10-cm dishes (2.5x10 6 cells per dish) and transfected with the psiU6BX vector, which included the target sequences for RGS4 or their scrambled sequences using Fugene6 (Invitrogen). The transfected FTC-133 cells were selected in a medium containing 0.6 mg/ml of neomycin (Geneticin; Gibco BRL, Table III . Sequences of specific double-stranded oligonucleotides inserted into the siRNA expression vector.
Carlsbad, CA). Subsequently, total RNA was extracted from the cells at 7 days after Geneticin selection and then the knock-down effect of the siRNAs was examined by a semiquantitative RT-PCR using specific primer sets: forward, 5'-CATCCACGAAACTACCTTCAACT-3' and reverse, 5'-TCTCCTTAGAGAGAAGTGGGGTG-3' as an internal control and 5'-CAAAGGGCTTGCAGGTCT-3' and 5'-TAG GCACACTGAGGGACCA-3' for RGS4. In 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay, cell viability was evaluated using the Cell-counting kit-8 (Dojindo, Kumamoto, Japan) at 7 or 14 days after the transfection according to the protocol of the supplier. After 21 days of the incubation, these cells were fixed with 4% paraformaldehyde and stained with Giemsa solution for colony formation assay.
Results

Identification of commonly up-regulated or down-regulated genes in thyroid carcinoma
. To obtain precise gene expression profiles of thyroid cancer cells, we employed LMM to purify both the cancerous cells and normal follicular epithelial cells ( Fig. 1A-F) . We estimated the proportion of parafollicular C cells in the microdissected population of normal follicular epithelial cells by measuring the signal intensities of CALCA (Calcitonin), which is expressed highly and specifically in parafollicular C cells (16) (17) (18) . When we compared the signal intensity of this gene in whole normal thyroid tissue with that of the microdissected normal follicular epithelial cells, the average ratio of signal intensity was calculated to be ~97.4%, indicating that the proportion of C cells in the microdissected normal follicular epithelial cells was ~2.6% (section Calculation of contamination percentage in Materials and methods) (19) .
We searched genes up-and down-regulated commonly in thyroid cancers according to the following criteria: i) genes for which we obtained expression data defined as described in Materials and methods in ≥50% (at least 9 of the 18 cases) of the cases examined; and ii) genes whose expression ratio was >5.0 or <0.2 in at least 50% of the informative cases. Under the criteria, a total of 243 transcripts were selected as genes that were commonly up-regulated (Table IV) and 138 as Table IV . Genes commonly up-regulated in thyroid cancer. Table IV . Continued. Full length insert cDNA YN63H06 Table IV . Continued. Table V . Genes commonly down-regulated in thyroid cancer.
-----------------------------------------------------------------------------------------------------No. Accession no. Gene symbol Gene name -----------------------------------------------------------------------------------------------------
cytosolic -----------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------No.
Accession no. TUSC3, TIMP1, FN1 and TMPRSS4 were previously reported to be genes that were activated in thyroid carcinoma (20, 21) . Furthermore, we identified 138 transcripts whose expression ratios were <0.2 in ≥50% of the informative thyroid cancers (Table V) . Among these down-regulated genes, 98 transcripts had been functionally characterized to a certain extent. They included ID3 (inhibitor of DNA binding 3), ID4 (inhibitor of DNA binding 4) and TFCP2L (Transcription factor CP2-like 1), which have been implicated in the growth suppression or regulation of transcription (22) (23) (24) . In particular, ID3 and ID4 were significantly down-regulated in each of the 18 thyroid cancer cases. TFCP2L was also significantly down-regulated in 17 of the 18 cases, indicating down-regulation of those genes may be related to thyroid cancer tumorigenesis.
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Identification of RGS4 as a molecular target gene for thyroid cancer therapy.
To validate the expression data obtained by microarray analysis, we performed semi-quantitative RT-PCR experiments for a total of 20 representative genes, which were frequently overexpressed in thyroid cancer cases, 
using 14 clinical thyroid cancer cases. We confirmed that these genes were highly expressed in all or most of the thyroid cancer cases examined, although their expression was undetectable in normal thyroid follicular epithelial cells (7 genes are shown in Fig. 2A) . The results of RT-PCR experiments using thyroid cancer materials were concordant to those of the microarray analysis.
Among the up-regulated genes in the thyroid cancer shown in Fig. 2A , we focused on the regulator of G-protein signaling 4, RGS4, for further biological analysis since it was overexpressed very commonly in clinical thyroid cancer samples, though not expressed in any of the normal human tissues examined except the brain by the microarray data (data not shown). Subsequent Northern blot analysis using an RGS4 cDNA fragment as a probe confirmed that an~3 kb transcript was hardly detectable in normal human tissues except the brain (Fig. 2B) . Expression of this gene was elevated in a very small subset of breast, esophagus, lung, colon, bladder, pancreatic and prostate cancers through our previous expression profile analysis (data not shown).
Inhibition of growth of thyroid cancer cells by specific small
interfering RNA against RGS4. To assess whether RGS4 is essential for the growth and survival of thyroid cancer cells, we constructed plasmids to express siRNAs against RGS4 (si#1 and si#2) as well as control plasmids (siRNA for Scramble and Mock vector) and transfected each of them into the FTC-133 thyroid cancer cell line, which endogenously expressed a high level of RGS4 mRNA. Among the siRNA constructs we tested, si#2 effectively knocked-down the expression of RGS4 mRNA, compared with control siRNAs (si-Scramble and si-Mock) (Fig. 3A) . We observed a significant decrease in the number of colonies (Fig. 3B ) and in the number of viable cells measured by MTT assay for the FTC-133 cells treated with si#2 (Fig. 3C) , indicating an important role of RGS4 in thyroid cancer cell survival and/or growth.
Discussion
Recent progress in genomic and molecular analysis has improved our understanding of the genesis of a wide range of human neoplasms. For thyroid carcinoma, several groups reported results of microarray-based expression profile analysis and demonstrated candidate genes that might be useful as diagnostic markers (4, 7, 9, 10, 21, (25) (26) (27) (28) (29) . However, tumor tissues are mixtures of various cell types such as inflammatory cells, stroma cells, endothelial cells and fibroblasts in addition to cancer cells and the proportions of each cell type vary significantly from one individual to another. Hence, the expression profile data using mRNAs isolated from bulk tumor tissues are very unlikely to reflect the exact changes during the course of thyroid carcinogenesis. In addition, normal thyroid is a mixture of different cell types. Since thyroid carcinomas except a medullary type of carcinoma are considered to originate from thyroid epithelial cells in follicles of the thyroid gland, it is better to use normal epithelial cells as a control to know the difference in expression levels related to the process in thyroid carcinogenesis. Therefore, in this study we performed LMM to enrich populations of papillary thyroid cancer cells as well as control normal thyroid follicular epithelial cells. A comparison of our data and one of the previous expression profile data of thyroid cancer using RNAs from bulk tumor tissues by means of microarray (30), only 71 of the 243 transcripts, that we identified to be commonly up-regulated in >50% of informative thyroid cancer cases shown in Table IV , overlapped to the bulk-expression profile data. We assume that these discrepancies were attributed mostly to the difference in the sample preparation processes and are confident that our data demonstrated more precisely the expression changes during the carcinogenesis process from thyroid epithelial to malignant cells. For example, genes highly expressed in parafollicular cells, though not in thyroid follicular epithelial cells, may be selected as down-regulated or unchanged genes in expression profiles from bulk tissues. To evaluate the purity of microdissected cell populations, we analyzed the expression of the CALCA, which is expressed abundantly in parafollicular C cells, in our gene expression profiling. By applying the microdissection procedure carefully, we were able to minimize the proportion of contaminating parafollicular C cells to as little as 2.6% in preparations of normal thyroid follicular epithelial cells. Indeed, a comparison of our data with the previous expression profile data of thyroid cancer by means of microarray (6, 10, 31, 32) , only 46 of the 138 transcripts, that we identified to be commonly down-regulated in >50% of informative thyroid cancer cases shown in Table V , overlapped to the bulk-expression profile data. Therefore, 92 genes, which had not been identified as down-regulated genes in previous reports, were identified as down-regulated genes in this study. In a list of the 92 down-regulated genes, which were identified in this study, we found CLIC3 (chloride intracellular channel 3), SDPR (serum deprivation response) and BEX1 (brain expressed, X-linked 1), which are reported as a regulator of cell growth, a regulator of the survival of cancer cells and a tumor suppressor, respectively (33) (34) (35) . This might suggest that a great majority of the down-regulated genes including genes with a tumor-suppressive function may be undetected in previous studies. We believe that it is crucial to perform the LMM system to purify as much as possible the populations of cancerous and normal epithelial cells obtained from surgical specimens to better understand genes, which are involved in the carcinogenesis. Some of the genes with an altered expression in most of thyroid cancers may play causal roles in thyroid carcinogenesis and also serve as molecular diagnostic markers and candidate targets for the development of novel therapeutic drugs for thyroid cancer. Among the up-regulated genes, FN1 (fibronectin 1), TNC (Tenascin C), TIMP1 (TIMP metallopeptidase inhibitor 1), TGFA (transforming growth factor α),
LGALS3 (Galecin3; lectin, galactoside-binding, soluble, 3) were previously reported as genes up-regulated in thyroid cancer (6, 10, 21, 26, (31) (32) (36) (37) (38) . The expression of the FN1 protein was indicated to be associated with malignant transformation because of its much higher expression in thyroid carcinomas than adenomas (39) . Most of papillary and medullary thyroid carcinomas demonstrated a strong TNC positivity in immunohistochemical analysis although its biological role in thyroid carcinoma is still unclear (40) . TIMP1 was reported as a diagnostic marker in distinguishing benign from malignant thyroid neoplasms and predicting the extent of this disease (41) . TGFA stimulates invasion and growth of thyroid cancer cells by binding to the EGFR and the TGF-α-mediated growth-promoting effect could be suppressed by an antagonist to the EGF receptor (42) . Moreover, TGFA was suggested to be involved in the regulation of thyroid cancer cell proliferation in an autocrine manner (43) .
LGALS3 was shown to be a useful marker in the diagnosis of thyroid cancer and was likely to be involved in the invasion and metastasis of cancer cells (44, 45) .
However, among the down-regulated genes, ID3 (inhibitor of DNA binding 3), ID4 (inhibitor of DNA binding 4) and TFCP2L1 (Transcription factor CP2-like 1) were implicated in the growth suppression or regulation of transcription. ID3 and ID4 proteins constitute a family of helix-loop-helix (HLH) transcription factors that are important regulators of cellular differentiation and proliferation (46) (47) (48) (49) . ID4 is suggested to modulate various key developmental processes and is involved in cell cycle control and cellular senescence (48) . Epigenetic silencing of this gene was found in gastric cancer and suggested its functions as a tumor suppressor (50) . Immunoblot and quantitative real-time (RT) polymerase chain reaction revealed a marked down-regulation of CRYAB (αB-crystallin), whose gene silencing was caused by the down-regulation of TFCP2L1 in malignant anaplastic thyroid carcinomas (ATC) and the ATC-derived cell line (51) . Table V included a large number of down-regulated genes, which were reported as down-regulated genes in previous microarray data using thyroid cancer samples (10, 21, 26, 31, 32, (36) (37) (38) . Among them, the down-regulation of DUSP1 (Dual specificity phosphatase 1), BCL2 (B-cell CLL/lymphoma 2), PAX8 (Paired box 8), and MT1G (Metallothionein 1G) were reported in multiple studies (10, 52) . The expression of DUSP1 was found to be reduced in thyroid cancer cell lines and down-regulated in a large fraction of thyroid carcinomas compared with normal tissue (53) (54) (55) (56) . Immunohistochemistry with an anti-bcl-2 monoclonal antibody on paraffin sections showed its high expression in normal follicular cells, while it appeared to be down-regulated in papillary, follicular and undifferentiated thyroid carcinomas (57) . PAX8 has a high expression in benign thyroid tissues and no or weak expression in thyroid cancers (57, 58) . Metallothionein 1G (MT1G) is a well-known gene whose protein is associated with the protection against DNA damage, oxidative stress and apoptosis (59) . Downregulation of MT1G in thyroid cancer has been reported by many authors (53) (54) (55) . In addition, the 92 down-regulated genes we identified here included EFEMP1 (EGF-containing fibulin-like extracellular matrix protein 1), ANGPTL1 (angiopoietin 1), and LIFR (leukemia inhibitory factor receptor α), which were implicated in growth suppression or apoptosis. It was reported that EFEMP1 had the capability of reducing tumor angiogenesis and tumor growth in vivo (60) . High frequency of the down-regulation of ANGPTL1 in tumor tissues, which is a pro-angiogenic factor, was also reported suggesting a role for this protein in tumor inhibition (61) . It was recommended that LIFR is required for differentiation and growth arrest of myeloid leukemic cells (62) .
Among the up-regulated genes in our list, in this study we further focused on Regulator of G-protein signaling 4 (RGS4) as a possible molecular target for thyroid cancer therapy due to frequent transactivation in thyroid cancers and its undetectable level of expression in any of the normal human adult tissues except the brain. We demonstrated that the knock-down of its expression level with siRNA resulted in the significant suppression of thyroid cancer cell growth, suggesting its essential role in the enhancement of cell growth. RGS4 belongs to the family of RGS proteins, which are regulatory molecules that act as GTPase activating proteins (GAPs) for G-α subunits of heterotrimeric G proteins. RGS4 contains an RGS domain, which is a conserved 120-amino acid sequence among each of the RGS family members. The expression of RGS4 in neurons is essential for embryonic neuronal development. More recently, RGS4 has been implicated in the involvement in tumor motility (63) .
Taken together, the up-regulated genes, including RGS4, identified through our precise expression profiles of thyroid cancers should shed light on a better understanding of thyroid carcinogenesis and provide useful information in discovering possible novel molecular targets for the development of thyroid cancer treatment and diagnostic tumor markers.
